source
- FDA pauses enrollment in Biohaven's epilepsy trials after earlier depression trial failureFDA placed a partial clinical hold on Biohaven's Kv7 potassium channel agonist, BHV-7000 (opakalim), halting enrollment of new patients in two late-stage focal epilepsy studies. The pause follows…
- Drugmakers Rethink Launch Strategies as MFN Pricing Rules Shake MarketA new Numerof & Associates report says that the rollout of Most Favored Nation (MFN) pricing rules is forcing drugmakers to overhaul how they choose launch markets. Executives surveyed said the Un…